13F Holdings
中文EN

CDNA CareDx, Inc.

Services-Medical Laboratories · Nasdaq · SEC CIK 1217234 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY38.9%
TTM net income YoY111.7%
TTM EPS YoY85.2%
Revenue 3-yr CAGR18.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin23.4%
Net margin25.9%
FCF margin—
EBITDA margin27.0%

Returns

ROE33.0%
ROA24.0%
ROIC (approx.)53.4%
Asset turnover0.93x

Leverage & solvency

Liabilities / assets27.1%
Debt / equity0.00x
Current ratio2.31x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.54x
Accruals ratio11.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$379.81M$333.79M$280.32M$321.79M$296.40M
R&D expense$71.43M$72.51M$82.42M$90.39M$76.53M
SG&A expense$107.56M$125.14M$118.84M$100.40M$74.96M
Operating income-$30.78M$40.77M-$203.36M-$77.23M-$29.73M
Pretax income-$21.08M$52.86M-$190.14M-$76.23M-$32.09M
Income tax$271,000$310,000$141,000$379,000-$1.43M
Net income-$21.35M$52.55M-$190.28M-$76.61M-$30.66M
EBITDA-$15.76M$54.96M-$188.98M-$65.64M-$20.93M
EPS (basic)-0.401.00-3.54-1.44-0.59
EPS (diluted)-0.400.93-3.54-1.44-0.59
Weighted avg. shares (diluted)53.29M56.62M53.76M53.32M52.24M
Balance sheet
Cash & equivalents$65.43M$115.27M$82.20M$90.44M$348.70M
Short-term investments$111.78M$145.96M$153.22M$203.17M$0
Receivables$42.63M$64.61M$51.06M$66.31M$59.76M
Inventory$26.70M$19.50M$19.47M$19.23M$17.19M
Current assets$257.13M$351.83M$313.71M$387.85M$433.36M
PP&E, net$32.97M$33.55M$35.25M$35.53M$22.04M
Goodwill$40.34M$40.34M$40.34M$37.52M$36.98M
Intangibles$31.96M$38.18M$45.70M$43.05M$50.20M
Total assets$413.23M$491.05M$466.83M$542.99M$566.62M
Current liabilities$89.85M$89.37M$78.07M$75.97M$77.30M
Total liabilities$110.13M$112.62M$205.50M$112.08M$100.75M
Shareholders' equity$303.10M$378.43M$261.33M$430.91M$465.88M
Shares outstanding50.92M54.77M51.50M53.53M52.92M
Cash flow statement
Operating cash flow$42.03M$38.05M-$18.39M-$25.24M-$19.29M
Investing cash flow$2.16M-$483,000$40.45M-$228.50M$47.71M
Financing cash flow-$93.39M-$5.61M-$29.61M-$4.54M$185.64M
Depreciation & amortization$15.02M$14.19M$14.39M$11.60M$8.80M
Stock-based compensation$34.86M$66.41M$49.09M$46.55M$36.08M
Share buybacks$87.77M$522,000$27.54M$642,000$0

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.